Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A major 2026 study suggests donor age affects survival differently in haploidentical and matched unrelated stem cell transplants, offering a more practical framework for choosing the best donor.
Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.
Adult AML with NUP98 rearrangements is a high-risk subtype marked by frequent FLT3-ITD and WT1 mutations, poor survival, and potential benefit from FLT3 inhibitors and stem cell transplant.
Single-cell profiling of WM during ibrutinib therapy revealed three tumor evolution patterns, a predictive WIP score, and T-cell dysfunction linked to resistance and disease progression.
Single-cell RNA sequencing suggests that childhood poverty exposure is associated with steroid-resistance signatures in leukemic blasts and adverse immune remodeling at diagnosis in standard-risk B-ALL.
In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.
A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.
A single-center validation study suggests the CTCL-PRO-20 may provide a reliable, disease-specific measure of quality of life in patients with cutaneous T-cell lymphoma.
Anti-CD117 CAR T-cell therapy demonstrated potent elimination of malignant mast cells in preclinical models of advanced systemic mastocytosis, offering a potential new treatment approach for this aggressive disorder.
A retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.
A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast can
這項涵蓋19國55個ICU的2003名患者研究發現，急性白血病危重患者總體ICU死亡率為45%，需機械通氣者達66%。年齡>65歲、AML診斷、化療期間入院等因素顯著增加死亡風險，但隨時間推移生存率有所改善。
This review synthesizes clinical evidence on busulfan pharmacokinetics, highlighting the critical role of TDM, the impact of body weight normalization, and significant drug interactions with deferasirox.
A French study reveals African ancestry significantly increases relapse risk in iTTP patients treated with rituximab. Key risk factors include male sex and prior relapses, with implications for personalized monitoring strategies.
A multicenter retrospective study suggests that MDS with isolated del(5q) and TP53 multihit alterations has substantially better survival than other low-blast TP53-multihit MDS, challenging how this subgroup should be classified.
A large multicenter study links specific bone marrow immune cell patterns to infection risk in multiple myeloma and proposes a clinically relevant immune score that may support minimally invasive monitoring.
Study reveals inadequate hemoglobin improvement at 20-24 weeks after iron therapy increases stillbirth and preterm birth risks in moderate iron deficiency anemia pregnancies, highlighting need for early intervention.
A prospective multicenter study reports excellent survival, no graft failure, and very low GVHD with a thiotepa-based reduced-intensity matched sibling transplant platform for severe sickle cell disease.
A 2026 single-center retrospective study suggests alpha-1-antitrypsin may offer favorable safety and encouraging activity in heavily pretreated gastrointestinal acute GVHD, though detailed outcome data and external validation remain essenti
A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.
Open language-specific specialty feeds and department pages.